Premium
Use of infliximab in pyoderma gangrenosum
Author(s) -
Hewitt Daniel,
Tait Clare
Publication year - 2007
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/j.1440-0960.2007.00344.x
Subject(s) - pyoderma gangrenosum , medicine , infliximab , dermatology , neutrophilic dermatosis , pyoderma , pathology , tumor necrosis factor alpha , disease
SUMMARY A 57‐year‐old man, with a 2‐year history of Crohn's disease, presented with a rapidly progressive abdominal ulcer. It was clinically and histologically consistent with pyoderma gangrenosum but it did not respond to either high‐dose oral prednisolone or intravenous hydrocortisone. Infliximab resulted in an early, dramatic and sustained improvement. His bowel symptoms, which flared a few weeks prior to the onset of pyoderma gangrenosum, only partially improved. Despite six infliximab infusions, the inflammatory bowel disease is poorly controlled, whereas the pyoderma gangrenosum remains healed.